Short-term supplementary SCF treatment enhances elimination of CML ST-HSCs and MPPs but not primitive LT-HSCs in nilotinib-treated mice. The gene discussed is KITLG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.